Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
The LX2006 update includes follow-up through 36 months, with neurological outcomes compared against an external natural-history cohort.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexeo Therapeutics (LXEO) announced upcoming scientific presentations and new interim LX2006 data showing neurologic improvements in participants with Friedreich ataxia.
Phase I/II results showed statistically significant improvement on mFARS, a neurologic rating scale, versus a propensity-matched control cohort from the UNIFAI natural history study. Participants with 24 months of follow-up (n=11) had mean improvement versus controls of 2.13 points per year, or 4.26 points over two years. A subset followed for 36 months (n=7) had mean improvement of over 4 points from baseline. Lexeo reported sustained or deepening cardiac and neurologic benefits. Presentations are scheduled at AHA on November 6–9 in Chicago and ICAR on November 10–13 in Atlanta, including preclinical desmoplakin and TNNI3 cardiomyopathy programs.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointLX2006 mFARS improvement was statistically significant versus propensity-matched controls from the UNIFAI natural history study.
- Minor point24-month participants (n=11) improved by 2.13 points annually, or 4.26 points over two years, versus controls.
- Minor point36-month subset (n=7) showed mean mFARS improvement of over 4 points relative to baseline.
- Minor pointCardiac measures, including left ventricular mass index and troponin, showed reported durable benefit and continued improvement.
Negative
- Minor pointLX2006 results remain interim phase I/II data; the neurological progression study is open-label and externally controlled.
Key Figures
- Participants with 24-month follow-up
- 11 participants
- LX2006-treated group
- Mean mFARS improvement
- 2.13 points per year
- 24-month follow-up; compared with propensity-matched control
- mFARS improvement over two years
- 4.26 points
- 24-month follow-up; compared with propensity-matched control
- Participants with 36-month follow-up
- 7 participants
- LX2006-treated subset
- Mean change from baseline
- Over 4 points
- 36-month follow-up subset
Historical Context
-
Previously reported early mFARS stabilization or improvement versus propensity-matched UNIFAI controls; current update extends follow-up.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
propensity-matched control cohort technical
lvmi medical
aav-based gene therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies
New LX2006 data to be presented at ICAR demonstrating cardiac and neurologic benefit up to 36 months, showing sustained or deepening improvement in mFARS outcomes over time
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced multiple presentations at the American Heart Association (AHA) Scientific Sessions 2026 and the International Congress for Ataxia Research (ICAR) 2026 both taking place in November.
“We are pleased to have multiple presentations at both AHA and ICAR, reflecting continued momentum across our cardiovascular and neurological genetic disease programs,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics. “We are particularly excited about the new mFARS data that will be presented at ICAR, which demonstrate durable neurologic benefit following LX2006 treatment and continued improvement over time. These findings build upon the encouraging cardiac benefits previously observed and further strengthen our belief that LX2006 has the potential to address the multisystem manifestations of Friedreich ataxia.”
LX2006 Clinical Data Update
New phase I/II interim clinical data continue to show sustained or deepening improvements across cardiac and neurologic measures of FA, including statistically significant improvement in mean mFARS scores for LX2006-treated participants compared to a propensity-matched control cohort from the UNIFAI natural history study.
- Among all participants with 24 months of follow-up (n=11), treatment with LX2006 resulted in a mean improvement of 2.13 points per year, or 4.26 points over two years, on the mFARS scale compared to propensity-matched control.
- Among a subset of participants with 36 months of follow-up (n=7), treatment with LX2006 resulted in further improvement, with a mean change of over 4 points relative to baseline
- Both neurologic and cardiac measures, including mFARS, left ventricular mass index (LVMI) and troponin, demonstrate durable benefit and continued improvement over time.
AHA Scientific Sessions 2026, November 6-9 in Chicago, Illinois
Abstract Title: LX2021, an AAV-Based Gene Therapy Improves Cardiomyopathy Phenotype and Lifespan in a Severe Desmoplakin Cardiomyopathy Mouse Model
Session Title: Late-breaking Basic Science: Frontiers in Cardiac Disease Mechanisms and Therapeutic Innovation
Format: Oral Presentation (27427)
Presenter: Jing Zhang, PhD
Date/Time: Saturday, November 7; 3:15 - 4:30 PM (session start/end); 3:30 - 3:45 PM CT (presentation start/end)
Location: S102D
Abstract Title: Mechanistic Insights and Gene Therapy Rescue in a Porcine Model of TNNI3 Cardiomyopathy
Session Title: Melvin L. Marcus Early Career Investigator Award in Cardiovascular Sciences Competition
Format: Oral Presentation (6873)
Presenter: Elizabeth Silver, MD
Date/Time: Saturday, November 7; 3:15 - 4:30 PM (session start/end); 4:00 - 4:15 PM CT (presentation start/end)
Location: S102BC
The full abstracts can be found on the AHA website.
ICAR 2026, November 10-13 in Atlanta, Georgia
Abstract Title: Safety and Preliminary Efficacy of AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia Cardiomyopathy
Session Title: Emerging and Existing Therapeutics
Format: Oral Presentation (EC9)
Presenter: Theresa Zesiewicz, MD, FAAN
Date/Time: Wednesday, November 11; 2:30 - 4:00 PM (session start/end); 3:06 - 3:24 PM (presentation start/end)
Location: Grand Ballroom
Abstract Title: Intravenous AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia: An Externally Controlled Open Label Study of Neurological Progression
Format: Poster Presentation (EC8)
Presenter: Christian Rummey, PhD
Date/Time: Wednesday, November 11; 6:00 - 7:30 PM
Location: Poster and Exhibitor Hall (D) - Cobb Convention Center
Abstract Title: Route of Administration and Systemic Immunity Differentially Influence Cerebellar Transduction by AAVrh.10hFXN
Format: Poster Presentation (EP26)
Presenter: Dolan Sondhi, PhD
Date/Time: Wednesday, November 11; 6:00 - 7:30 PM
Location: Poster and Exhibitor Hall (D) - Cobb Convention Center
Abstract Title: Amplifying the Patient Voice: Impact of a Friedreich Ataxia Cardiac Advisory Council in Its First Year
Format: Poster Presentation (C115)
Presenters: Joslyn Crowe & Hayden Howard
Date/Time: Thursday, November 12; 6:00 - 7:30 PM
Location: Poster and Exhibitor Hall (D) - Cobb Convention Center
The full abstracts can be found on the ICAR website.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026 and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lexeo’s LX2006 update show for neurological outcomes in Friedreich ataxia?
LX2006-treated participants with 24 months of follow-up (n=11) showed mean mFARS improvement of 4.26 points over two years versus propensity-matched controls. A subset with 36 months of follow-up (n=7) showed mean improvement of over 4 points relative to baseline; these comparisons use different reference points.